$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
免疫药纳武单抗用于黑色素瘤的疗效和安全性
2025-10-19 11:44:20
Check Details
威罗非尼+考比替尼可显著提高BRAF突变阳性晚期黑色素瘤患者无进展生存期
2025-10-19 11:44:20
Check Details
【用药须知】曲美替尼是什么药?用于治疗什么病症?
2025-10-19 11:44:20
Check Details
【带你知道】黑色素瘤免疫治疗药物纳武单抗的疗程及价格
2025-10-19 11:44:20
Check Details
治疗黑色素瘤的靶向药有哪些?贝美替尼也是吗?看完你知道了
2025-10-19 11:44:20
Check Details
【重磅】晚期黑色素瘤治疗新选择:威罗非尼+考比替尼
2025-10-19 11:44:20
Check Details
免疫药纳武单抗经FDA批准的适应症有哪些?
2025-10-19 11:44:20
Check Details
纳武单抗使用说明|注意事项|禁忌|不良反应
2025-10-19 11:44:20
Check Details
【热点】黑色素瘤迎来新选择:贝美替尼+康奈非尼
2025-10-19 11:44:20
Check Details
纳武单抗+伊匹单抗可以显著改善晚期黑色素瘤患者生存期
2025-10-19 11:44:20
Check Details
【关注度高】曲美替尼在医保可报销药品范围内吗?
2025-10-19 11:44:20
Check Details
黑色素瘤术后患者可以使用纳武单抗吗?
2025-10-19 11:44:20
Check Details
1
2
...
663
664
665
666
667
668
669
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
2
Tucatinib HER2 TKI: With Trastuzumab + Capecitabine, Diarrhea and Hepatotoxicity Monitoring
3
Pemigatinib for FGFR2-Rearranged Cholangiocarcinoma: Eligibility, Response Limits, Hyperphosphatemia and Ocular Monitoring
4
Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs
5
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
6
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
7
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
8
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
9
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
10
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
11
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
12
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma